Free tool
FAERS Monitor: Mulpleta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210923 or its brand name (Mulpleta, Lusutrombopag). Reports on generic versions are filed under their own applications.
Reports
39
Serious
27
69% of reports
Hospitalization
7
Death reported
8
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death3
- drug ineffective3
- nausea3
- ascites2
- diarrhoea2
- headache2
- hospitalisation2
- mesenteric vein thrombosis2
- pain2
- pancytopenia2
- portal vein thrombosis2
- pulmonary embolism2
- shock haemorrhagic2
- acute hepatic failure1
- arterial injury1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 7 |
| 2019 | 10 |
| 2020 | 7 |
| 2021 | 1 |
| 2022 | 7 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,120 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| mesenteric vein thrombosis | 2 | 1085.1 | 280.9 | 1,215 |
| arterial injury | 1 | 723.7 | 104.4 | 180 |
| portal vein thrombosis | 2 | 334.1 | 86.6 | 373 |
| shock haemorrhagic | 2 | 132.5 | 34.4 | 146 |
| acute hepatic failure | 1 | 39.5 | 5.7 | 9 |
| ascites | 2 | 36.7 | 9.5 | 38 |
| pancytopenia | 2 | 19.3 | 5.0 | 19 |
| pulmonary embolism | 2 | 11.4 | 2.9 | 10 |
| hospitalisation | 2 | 7.0 | 1.8 | 5 |
| nausea | 3 | 2.0 | 0.7 | 1 |
| death | 3 | 1.9 | 0.6 | 1 |
| pain | 2 | 1.8 | 0.5 | 0 |
| headache | 2 | 1.7 | 0.4 | 0 |
| diarrhoea | 2 | 1.7 | 0.4 | 0 |
| drug ineffective | 3 | 1.2 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.